SCHEMBL534677

SCHEMBL534677

CCO/N=C\C(C)(C)NC(=O)C(CC)Oc1ccc2ncc(I)cc2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.36
TP53 P04637 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MET P08581 5/20 0.35
ALDH1A1 P00352 7/20 0.34
LMNA P02545 3/20 0.34
KDR P35968 2/20 0.34
KDM4E B2RXH2 2/20 0.34
AURKA O14965 1/20 0.34
ABL1 P00519 1/20 0.34
LCK P06239 1/20 0.34
FYN P06241 1/20 0.34
YES1 P07947 1/20 0.34
FGFR2 P21802 1/20 0.34
EPHA2 P29317 1/20 0.34
LTK P29376 1/20 0.34
AXL P30530 1/20 0.34
FLT3 P36888 1/20 0.34
MST1R Q04912 1/20 0.34
PTK6 Q13882 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL534678 1.00 MAPT (0.36) MAPTTP53SMN1; SMN2METALDH1A1
SCHEMBL535288 0.93 MAPT (0.35) MAPTTP53SMN1; SMN2METALDH1A1
SCHEMBL535287 0.93 MAPT (0.35) MAPTTP53SMN1; SMN2METALDH1A1
SCHEMBL534844 0.93 MAPT (0.36) MAPTTP53SMN1; SMN2METALDH1A1
SCHEMBL534843 0.93 MAPT (0.36) MAPTTP53SMN1; SMN2METALDH1A1
SCHEMBL535165 0.91 MAPT (0.35) MAPTTP53SMN1; SMN2METALDH1A1
SCHEMBL535164 0.91 MAPT (0.35) MAPTTP53SMN1; SMN2METALDH1A1
SCHEMBL534541 0.91 HSD17B10 (0.36) MAPTTP53SMN1; SMN2METALDH1A1
SCHEMBL534540 0.91 HSD17B10 (0.36) MAPTTP53SMN1; SMN2METALDH1A1
SCHEMBL535229 0.87 MET (0.35) MAPTTP53SMN1; SMN2METALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507509-B2 Saturated and insaturated bi- or tricyclic aryloxyacetamine derivatives and their use as fungicides SYNGENTA CROP PROTECTION LLC (US) 2013-08-13 US disclosed
EP-2185518-B1 Aryloxyacetamide derivatives and their use as fungicides SYNGENTA PARTICIPATIONS AG (CH) 2012-02-08 EP disclosed
US-20100298356-A1 SATURATED AND INSATURATED BI- OR TRICYCLIC ARYLOXYACETAMINE DERIVATIVES AND THEIR USE AS FUNGICIDES SYNGENTA CROP PROTECTION, INC. (US) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298356-A1 SATURATED AND INSATURATED BI- OR TRICYCLIC ARYLOXYACETAMINE DERIVATIVES AND THEIR USE AS FUNGICIDES CYP1A2, CYP1B1, CYP1A1 MAPT 921/4885TP53 3773/4885SMN1; SMN2 2208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.